BIOSYNTH
9.5.2023 11:01:34 CEST | Business Wire | Press release
Biosynth, a supplier of critical raw materials to the life science industry, announces today that it has acquired Cambridge Research Biochemicals (“CRB”), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.
CRB brings a wealth of expertise to Biosynth’s peptide division, which has existing operations in the US and the Netherlands. This includes leading expertise in complex peptide chemistry and fluorescent dye labelling. CRB also brings additional custom antibody capacity in Europe, to support customers through the generation of novel, complex or unusual mono- and poly-clonal antibodies unavailable in catalogs.
Dr. Urs Spitz, CEO and President of Biosynth, said, “CRB has a long history in the peptide and antibody field, and we are excited to welcome their highly skilled team to our growing peptide division. Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high quality antibodies.”
“We are excited to be joining the Biosynth family”, added Emily Humphrys, Managing Director of Cambridge Research Biochemicals. “As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus.”
--ends--
About Biosynth
Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing and distribution facilities. Supplying the pharmaceutical, life science and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at www.biosynth.com.
About Cambridge Research Biochemicals
Cambridge Research Biochemicals (www.crbdiscovery.com) is a leading independent producer of custom-made peptide and antibody tools, supplying researchers in the pharmaceutical, life science and academic sectors worldwide. The primary applications of its products are as custom-made, laboratory scale reagents for proof of principal studies within early phase drug discovery and to support biomarker programmes in clinical studies. The company produces all flavours of peptides from simple to modified, stable and radio-labelled to dye labelled from milligrams to gram-scale to the highest levels of purity. In addition, CRB is a recognised expert at generating highly specific and targeted antibodies (both polyclonal and monoclonal). Fluorescent dye labelling is also a focus.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005621/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euroAtlantic Airways Adds Second A330-300, Expanding Widebody Capacity28.10.2026 11:00:00 CET | Press release
euroAtlantic Airways (“EAA”), a Njord Partners portfolio company and a Portuguese ACMI and charter airline, has added a second Airbus A330-300 leased from Jackson Square Aviation (JSA), further expanding its widebody capacity. The second aircraft arrived in Portugal on 28 October 2026, bringing EAA’s total fleet size to eight. The first aircraft, CS-TGI, has already been inducted into EAA’s Air Operator Certificate and is operating commercial flights, including short-term ACMI and charter assignments. The second aircraft, an Airbus A330-300 which will carry the registration CS-TGJ, will now go through induction into EAA’s Air Operator Certificate, subject to the usual regulatory approvals. Both aircraft are leased from JSA and seat 290 passengers across three classes. The addition of the second aircraft strengthens EAA’s ability to serve a diversified range of customer requirements across global markets. In line with its long-term plans, EAA is well positioned for continued disciplined
Blue Matter Acquires Cognite, a Leading Healthcare Communications Agency28.10.2026 11:00:00 CET | Press release
Blue Matter, a world-class consulting firm serving the life sciences industry, today announced the acquisition of Cognite, a leading global healthcare communications agency that helps pharmaceutical and biotech companies bring science to life through an impressive range of scientific, medical, and commercial communications services. Cognite represents a significant step forward in strengthening Blue Matter’s growing range of communications capabilities. “Blue Matter is recognized as a valuable strategic resource and a thought leader when it comes to corporate, portfolio, product, and functional strategy in biopharma,” said Blue Matter CEO Ashwin Dandekar. “Over the past few years, we’ve been systematically bringing together the creative and communications capabilities that are often so crucial to bringing those strategies to life with healthcare providers, patients, payers, investors, and other stakeholders. Cognite’s array of capabilities, creativity, and team culture are a perfect fi
Financial Services Increases AI Investment Faster Than Wider Market, While Maturity Remains Level28.10.2026 09:56:00 CET | Press release
HTEC research finds 42% of financial services and insurance executives report significantly increased AI investment, compared with 28% across industries, while AI maturity remains in line with the wider market HTEC, the global AI technology and engineering leader, today released its research on AI Value realization in financial services and Insurance. Organizations in this sector are increasing AI investment more aggressively than the wider market, but the sector has yet to establish a corresponding lead in AI maturity, according to new research from HTEC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028854882/en/ HTEC, the global AI technology and engineering leader, today released its research on AI Value realization in financial services and Insurance. Organizations in this sector are increasing AI investment more aggressively than the wider market, but the sector has yet to establish a corresponding lead in AI matur
Powens Launches Connector Agentic Factory, an AI System to Build and Fix Open Finance Connectors28.10.2026 09:00:00 CET | Press release
A new chapter in Powens' ambition: Connector Agentic Factory is Powens' new AI system to build, extend and repair Open Finance connectors, a key step toward becoming the most complete and reliable Open Finance infrastructure in EuropeAlready at work: 12 new connectors delivered across Europe, and repairs completed in minutes rather than daysNo control loss: every connector the AI proposes is still reviewed and approved by Powens engineers before it goes live Powens, a leading European Open Finance infrastructure provider, today announced the launch of its Connector Agentic Factory, an internal AI system that is capable of building new Open Finance connectors and repairing existing ones. Connectors are the technical links that let banks, fintechs, and financial apps securely retrieve a customer's financial data, or make payments, from a bank or other institution. Powens maintains more than 1,800 of them across Europe, and they underpin the services that banks, fintechs, lenders, wealth
Ant International CEO: Achieving Inclusion Is Critical to Re-Globalisation, and AI Will Accelerate It by Democratising Opportunities28.10.2026 07:24:00 CET | Press release
Speaking at the United Nations Trade and Development (UNCTAD) World Investment Forum 2026 panel, “Investing in AI for an Inclusive Digital Future”, Ant International CEO Peng Yang called for a new, inclusive “re-globalisation” project that harnesses AI and digital connectivity to give small and medium-sized enterprises (SMEs) greater access to global markets and opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027567337/en/ Ant International CEO Peng Yang speaks at the United Nations Trade and Development (UNCTAD) World Investment Forum 2026 “Globalisation 1.0 mostly benefited large enterprises, and a lot of SMEs very rarely got to participate in the global economy,” said Yang. “Achieving inclusion is critical to re-globalisation, and AI will accelerate it by democratising opportunities.” 1. The limitation of Globalisation 1.0 and how AI and other innovations offer a chance to improve Yang said one of the gre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom